Methods for treating neurodegenerative diseases

By using polymer-flavonoid conjugates and flavonoid oligomers to encapsulate antibodies in nanocomposites, drugs can be delivered across the blood-brain barrier, solving the treatment challenges of neurodegenerative diseases and enabling the safe and effective application of anti-CD3 antibodies, thus reducing neuroinflammation and disease progression.

CN121443318APending Publication Date: 2026-01-30SUNTEC MEDICAL INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202480034000.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-05
Filing Date
2024-06-05
Publication Date
2026-01-30

AI Technical Summary

Technical Problem

Existing treatments cannot effectively reverse neuronal degeneration, oxidative stress, and inflammation, leading to the incurability of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Furthermore, anti-CD3 antibody therapy has serious side effects such as cytokine release syndrome and leukopenia.

Method used

Using polymer-flavonoid conjugates or flavonoid oligomers as the shell of nanocomposites, antibody drugs such as anti-CD3 are encapsulated to form MINC-drug agents. These agents deliver drugs across the blood-brain barrier, modulate immune responses, reduce neuroinflammation, and decrease antibody toxicity.

Benefits of technology

It effectively treats neurodegenerative diseases, reduces abnormal protein aggregation, lowers oxidative stress, enhances neuronal protection and regeneration, reduces disease progression, and reduces antibody toxicity side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121443318A_ABST
    Figure CN121443318A_ABST
Patent Text Reader

Abstract

The present invention provides a method of treating a neurodegenerative disease. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate or nanocomposite, the nanocomposites have an outer shell comprising one or more polymer-flavonoid conjugates and, optionally, an inner shell comprising one or more flavonoid oligomers, as well as drugs, such as anti-CD3 or anti-CD33, encapsulated within these shells. The methods of the invention allow therapeutically effective substances to pass through the blood-brain barrier to treat neurodegenerative diseases. The methods of the invention are effective in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and Huntington's disease.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Aldehyde conjugated flavonoid preparations

    WO2006124000A1

  • Method of delivering an Anti-cancer agent to a cell

    WO2009054813A1

  • Anti-cancer agent delivery vehicles capable of improved laoding

    WO2011112156A1

  • A micellar nanocomplex

    WO2015171079A1